Meta Description (SEO): A recent AIIMS Gorakhpur study highlights rising sudden deaths after COVID-19 vaccination in India. Learn about AEFI data, cardiovascular risks, and vaccine safety concerns.
India Sounds the Alarm on COVID-19 Vaccine Safety
India is now raising concerns over the rise in sudden deaths among COVID-19 vaccinated individuals, following a study conducted by top researchers at AIIMS Gorakhpur. The research, published in the journal Therapeutic Advances in Vaccines and Immunotherapy, analyzed government-reported cases of Adverse Events Following Immunization (AEFI) and found a worrying trend in vaccine-related fatalities.
Key Findings of the Study
1. Data Based on Government AEFI Reports
The study examined 2708 serious AEFI cases reported between January 2021 and May 2023.
Cases included deaths, strokes, cardiac arrests, and blood clot-related complications.
2. Cardiovascular Deaths Linked to Vaccination
Researchers noted that male recipients showed a significantly higher risk of cardiovascular injury leading to sudden deaths.
This has raised questions about the long-term safety of COVID vaccines in India.
3. No mRNA Vaccines in India’s Rollout
Interestingly, India never approved Pfizer or Moderna mRNA vaccines for mass use.
The government refused liability immunity to global pharma companies, which kept mRNA shots out of the Indian vaccination drive.
4. Gaps in Safety Monitoring
The findings suggest that India’s vaccine safety monitoring systems may have under-reported long-term side effects.
Conditions such as cancer or other chronic diseases were not even considered in AEFI classifications.
Why This Study Matters
The AIIMS research raises critical questions about:
Vaccine safety surveillance in India
Accuracy of AEFI reporting systems
Gender-specific risks, particularly among young and middle-aged men
The need for transparent long-term safety data on COVID vaccines
India’s COVID-19 Vaccination Context
India launched one of the world’s largest vaccination drives in January 2021.
Approved vaccines included Covishield (Oxford-AstraZeneca) and Covaxin (Bharat Biotech).
By mid-2023, over a billion doses were administered.
While vaccines played a key role in controlling COVID-19, concerns about rare but severe adverse reactions are now surfacing.
SEO Keywords to Target
Sudden deaths after COVID vaccine in India
AIIMS study on COVID vaccine safety
COVID vaccine side effects India
AEFI data India COVID vaccine
Covishield sudden death risk
Final Thoughts
The AIIMS Gorakhpur study has sparked a fresh debate in India over the safety of COVID-19 vaccines and the transparency of AEFI reporting systems. While vaccines undoubtedly saved millions of lives during the pandemic, the evidence of sudden deaths and cardiovascular risks calls for stronger surveillance and independent investigation. As India continues to balance public health protection and vaccine safety, this study could mark the beginning of greater accountability and stricter vaccine monitoring.